(HIMS) Hims Hers Health - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US4330001060
HIMS: Medicine, Cosmetics, Supplements, Condoms, Vibrators, Shampoos
Hims & Hers Health, Inc. is a leading telehealth platform that bridges the gap between consumers and licensed healthcare professionals across the United States, the United Kingdom, and other international markets. This digital health company offers a seamless online experience, allowing users to access a variety of prescription and non-prescription health and wellness products through their websites and mobile app.
The companys product portfolio is thoughtfully curated, focusing on key areas such as sexual health, skincare, hair care, and general wellness. In the sexual health category, Hims & Hers provides solutions like condoms, lubricants, and climax delay sprays. Skincare offerings include a range of products from moisturizers and serums to sunscreens. For hair care, they offer shampoos, conditioners, and treatments like minoxidil. Additionally, they provide wellness products such as melatonin and biotin, catering to a broad audience seeking convenient health solutions.
Hims & Hers operates on a subscription model, which is appealing for its recurring revenue potential. This model ensures consistent engagement with customers, who can receive regular shipments of their necessary medications and wellness products. Beyond direct sales, the company also partners with wholesale distributors to expand its market reach, further diversifying its revenue streams.
From a financial perspective, Hims & Hers is listed on the NYSE under the ticker symbol HIMS. With a market capitalization of approximately $12.9 billion, the company presents an interesting case for investors. The price-to-earnings (P/E) ratio stands at 134.50, indicating high expectations for future growth. The forward P/E of 121.95 suggests that analysts anticipate continued expansion. The price-to-book (P/B) ratio of 29.38 highlights the markets confidence in the companys intangible assets and growth prospects. The price-to-sales (P/S) ratio of 10.41 reflects the premium investors are willing to pay for its revenue generation capabilities.
Overall, Hims & Hers Health, Inc. is strategically positioned in the telehealth and consumer health market, offering a unique blend of digital healthcare services and wellness products. This combination, along with its subscription-based revenue model, makes it an attractive option for investors looking to capitalize on the growing digital health trend. For more information, visit their website at https://www.forhims.com.
Additional Sources for HIMS Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
HIMS Stock Overview
Market Cap in USD | 7,987m |
Sector | Consumer Defensive |
Industry | Household & Personal Products |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 2019-09-13 |
HIMS Stock Ratings
Growth 5y | 58.0% |
Fundamental | 40.7% |
Dividend | 0.0% |
Rel. Strength Industry | 128 |
Analysts | 3.38/5 |
Fair Price Momentum | 31.38 USD |
Fair Price DCF | 5.83 USD |
HIMS Dividends
No Dividends PaidHIMS Growth Ratios
Growth Correlation 3m | 71.8% |
Growth Correlation 12m | 82% |
Growth Correlation 5y | 24.4% |
CAGR 5y | 28.09% |
CAGR/Max DD 5y | 0.32 |
Sharpe Ratio 12m | 0.61 |
Alpha | 97.33 |
Beta | 4.40 |
Volatility | 114.58% |
Current Volume | 17092.9k |
Average Volume 20d | 29912.1k |
As of March 15, 2025, the stock is trading at USD 33.14 with a total of 17,092,941 shares traded.
Over the past week, the price has changed by -7.82%, over one month by -45.20%, over three months by +6.05% and over the past year by +130.14%.
Partly, yes. Based on ValueRay Fundamental Analyses, Hims Hers Health (NYSE:HIMS) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 40.65 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of HIMS as of March 2025 is 31.38. This means that HIMS is currently overvalued and has a potential downside of -5.31%.
Hims Hers Health has received a consensus analysts rating of 3.38. Therefor, it is recommend to hold HIMS.
- Strong Buy: 3
- Buy: 2
- Hold: 6
- Sell: 1
- Strong Sell: 1
According to ValueRays Forecast Model, HIMS Hims Hers Health will be worth about 37.7 in March 2026. The stock is currently trading at 33.14. This means that the stock has a potential upside of +13.64%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 43.4 | 31.1% |
Analysts Target Price | 26.2 | -20.9% |
ValueRay Target Price | 37.7 | 13.6% |